Oppenheimer raised the firm’s price target on Pharming (PHAR) to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group Reports Strong Q3 2025 Growth
- Pharming Group Reports Strong Q3 2025 Financial Growth and Strategic Updates
- Pharming Group to Present New Data at ACAAI 2025
- Pharming Group Announces Restructuring to Cut Costs and Boost Growth
- Pharming announces 20% net reduction in non-commercial, non-medical headcount